Ocata Therapeutics Inc fka OCAT

[lasers]

Since Astellas products pipeline is extremely poor due to its expiring Patents and Drug exclusivities, then they must acquire/merge with other Pharmas to continue with revenues for their shareholders. Astellas is Japan's 2nd largest pharma.

If Astellas cannot acquire the needed +50% shares O/S of the +42Mil shs (approx 21mil shs) for $OCAT then it can be expected IMO that they will raise their $8.50 Bid higher until they are able to acquire the 21 mil shs needed. May 16, 2016 is their official end period per SEC documentation.

The Hedge Fds and/or Pharmas that have purchased the 25 mil shs from the open mkt purchases since Nov 10 will be the determinant factors as to what PPS they force the bidding up to.

JMHO